title: Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
authors.affiliation: Corresponding author: Katherine Q. Philla, katherine.q.philla.mil@health.mil.
authors.forename: Katherine Q
authors.initials: KQ
authors.lastname: Philla
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Bauer
authors.forename: Karen S
authors.initials: KS
authors.lastname: Vogt
authors.forename: Siri Atma W
authors.initials: SA
authors.lastname: Greeley
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D004252:DNA Mutational Analysis; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D005500:Follow-Up Studies; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007223:Infant; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics* / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D000099161:Kcnj11 Channel
chemical_list: D001786:Blood Glucose; D005905:Glyburide; D007004:Hypoglycemic Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D013453:Sulfonylurea Compounds; D000099161:Kcnj11 Channel